Sinovac Biotech Ltd (SVA) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Sinovac Biotech Ltd (SVA) has a cash flow conversion efficiency ratio of 0.012x as of December 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($146.01 Million) by net assets ($12.02 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See debt-free asset ratio of Sinovac Biotech Ltd to measure how much of total assets are equity-financed.
Sinovac Biotech Ltd - Cash Flow Conversion Efficiency Trend (2000–2023)
This chart illustrates how Sinovac Biotech Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Sinovac Biotech Ltd (SVA) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Sinovac Biotech Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sinovac Biotech Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Changhong Meiling Co Ltd
SHE:000521
|
-0.004x |
|
J.S. Corrugating Machinery Co Ltd
SHE:000821
|
0.038x |
|
COFCO Joycome Foods Limited
F:0M7
|
0.055x |
|
Zhejiang He Chuan Technology Corp. Ltd. A
SHG:688320
|
N/A |
|
Shenzhen Expressway Company Limited
F:SHZH
|
0.027x |
|
Chongqing Landai Powertrain Corp Ltd
SHE:002765
|
-0.007x |
|
New York Mortgage Trust Inc
NASDAQ:NYMT
|
0.028x |
|
Yunnan QuakeSafe Seismic Isolation Technologies Co Ltd Class A
SHE:300767
|
0.032x |
Annual Cash Flow Conversion Efficiency for Sinovac Biotech Ltd (2000–2023)
The table below shows the annual cash flow conversion efficiency of Sinovac Biotech Ltd from 2000 to 2023. For the full company profile with market capitalisation and key ratios, see market value of Sinovac Biotech Ltd.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | $12.02 Billion | $106.02 Million | 0.009x | +114.54% |
| 2022-12-31 | $12.71 Billion | $-770.75 Million | -0.061x | -105.48% |
| 2021-12-31 | $13.88 Billion | $15.35 Billion | 1.106x | +158.56% |
| 2020-12-31 | $1.12 Billion | $479.31 Million | 0.428x | +285.70% |
| 2019-12-31 | $352.19 Million | $39.07 Million | 0.111x | +307.75% |
| 2018-12-31 | $291.93 Million | $7.94 Million | 0.027x | -94.10% |
| 2017-12-31 | $129.67 Million | $59.76 Million | 0.461x | +486.55% |
| 2016-12-31 | $129.67 Million | $-15.46 Million | -0.119x | -486.47% |
| 2015-12-31 | $136.50 Million | $4.21 Million | 0.031x | +143.17% |
| 2014-12-31 | $141.73 Million | $-10.13 Million | -0.071x | -284.07% |
| 2013-12-31 | $143.64 Million | $5.58 Million | 0.039x | +130.91% |
| 2012-12-31 | $129.44 Million | $-16.25 Million | -0.126x | -230.93% |
| 2011-12-31 | $145.30 Million | $13.94 Million | 0.096x | +199.25% |
| 2010-12-31 | $147.76 Million | $-14.28 Million | -0.097x | -116.86% |
| 2009-12-31 | $84.47 Million | $48.41 Million | 0.573x | +192.64% |
| 2008-12-31 | $53.64 Million | $10.50 Million | 0.196x | +49.30% |
| 2007-12-31 | $32.90 Million | $4.32 Million | 0.131x | +270.93% |
| 2006-12-31 | $21.31 Million | $-1.64 Million | -0.077x | -12.10% |
| 2005-12-31 | $16.51 Million | $-1.13 Million | -0.068x | +30.71% |
| 2004-12-31 | $15.56 Million | $-1.54 Million | -0.099x | +37.57% |
| 2003-12-31 | $10.89 Million | $-1.72 Million | -0.158x | +72.89% |
| 2002-12-31 | $99.44K | $-58.05K | -0.584x | -180.57% |
| 2001-12-31 | $-682.96K | $-494.80K | 0.724x | 0.00% |
| 2000-12-31 | $-682.96K | $-494.80K | 0.724x | -- |
About Sinovac Biotech Ltd
Sinovac Biotech Ltd., a biopharmaceutical company, focuses in the research, development, manufacture, and commercialization of vaccines against human infectious diseases in the People's Republic of China. The company's product portfolio includes vaccines against hepatitis A and B; hand, foot, and mouth diseases caused by enterovirus 71 (EV71); seasonal influenza; H5N1 and H1N1 pandemic influenza;… Read more